MoonLake Immunotherapeutics Announces Board Changes and Incentives
Clear Street Launches Healthcare & Biotechnology Equity Research
Stifel Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $77
We Think MoonLake Immunotherapeutics (NASDAQ:MLTX) Can Afford To Drive Business Growth
Jefferies Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $65
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $75
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
